by Joseph Schlessinger
VISION	SU11248: Genesis of a New Cancer Drug The development of a promising RTK inhibitor Email: Joseph Schlessinger - joseph.schlessinger@yale.edu The Scientist 2005, 19(7):17 Published   11 April 2005

Every drug has a story behind it. Here, I condense 25 years of hard work by hundreds of people by focusing on key events and characters that shaped the discovery of SU11248, a new cancer drug. Cancers remain an immense problem, but this story has an affirmative message: Investment in basic research, the mining of that research for promising leads, and the relentless, dedicated development of these leads can yield new therapies.

(continued >>)

To continue reading this full article, you must be a subscriber to The Scientist.

You are only a few minutes away from unlimited access.

If you already have an online subscription, please Log-In Now.
New to The Scientist? Register to get access to a selection of our content, interactive features and useful tools free without a subscription.

Subscribe to The Scientist to get unlimited access to our premium content

Get unlimited access to this article and over 20 years of The Scientist archives. You won’t miss a word – all for as little as $4.95.  Subscribe now.

The Scientist offers site licenses to institutions and organizations. Recommend us to your librarian and get online access through your place or work or study.